Indo Borax & Chemicals Limited to Consider Q2 FY27 Results
Key highlights
- Indo Borax’s board will consider Q2 FY27 and half-year results on November 6, 2026.
- Q1 FY27 revenue rose 31.34% year-on-year to ₹70.36 crore.
- Q1 FY27 net profit increased 59.31% year-on-year to ₹16.25 crore.
- Q1 FY27 EBITDA margin expanded to 28.14% from 22.8% a year earlier.
powered by IRIS

Indo Borax & Chemicals Limited will consider its unaudited Q2 FY27 and half-year results on November 6, 2026, following Q1 FY27 revenue growth of 31.34% year-on-year to ₹70.36 crore and a 59.31% rise in net profit to ₹16.25 crore.
Know Indo Borax & Chemicals inside out
Results, valuation, peers and who's buying, in one view.
When will Indo Borax announce its Q2 FY27 results?
Indo Borax will place its standalone and consolidated unaudited financial results for the quarter and half-year ended September 30, 2026 before its board on November 6, 2026. The company informed BSE on October 30 that its board meeting had been scheduled to consider and approve these results.
The Q2 FY27 period covers July 1 to September 30, 2026. The board-meeting disclosure replaces earlier uncertainty over the timing of the results. Under listing requirements, September-quarter results must be filed within 45 days of the quarter-end, with November 14, 2026 representing the outer reporting deadline cited in the available information.
The company has also stated that its trading window for insider transactions was closed from October 1, 2026. It will reopen 48 hours after the declaration of the unaudited results, in line with SEBI’s insider-trading regulations.
What did Indo Borax report in Q1 FY27?
Indo Borax reported strong year-on-year growth in Q1 FY27, with consolidated revenue rising to ₹70.36 crore and net profit increasing to ₹16.25 crore. The June 2026 quarter established the latest reported financial base against which investors may assess the September-quarter release.
Revenue was up 31.34% from ₹53.57 crore in Q1 FY26 and rose 11.66% sequentially from ₹63.01 crore in Q4 FY26. EBITDA increased 62.16% year-on-year to ₹19.80 crore, while the EBITDA margin widened to 28.14% from 22.8% a year earlier.
The sharper increase in EBITDA and profit than in revenue indicates improved operating conversion during the quarter. PAT margin was reported at 22.3%, compared with 18.0% in the year-ago period, while earnings per share increased from ₹3.18 to ₹5.07.
What will the September-quarter results be compared against?
Indo Borax’s Q2 FY27 performance will be compared with a Q2 FY26 revenue base of ₹58.00 crore and net profit of about ₹16 crore. The company was reported to have posted net profit of ₹16.09 crore in Q2 2025, compared with ₹9.03 crore in Q2 2024.
The prior-year comparison is relevant because the company enters the September 2026 quarter after a strong June-quarter performance. However, no verified revenue, profit, or consensus estimate for Q2 FY27 has been provided in the available material, so the November 6 board meeting should not be treated as confirmation of any earnings outcome before the formal filing.
The Q1 FY27 results were supported by demand for boron-based chemicals across steel, glass, ceramics, agriculture, electronics and detergents. Suresh Kalra, Managing Director and CEO, said the company was seeing robust demand across these end-use segments.
Got a follow-up? Ask IRIS
Why are margins and demand trends important for Indo Borax?
Margins and capacity utilisation are important because Indo Borax’s Q1 FY27 EBITDA margin rose to 28.14%, from 20.4% in the preceding March quarter. Revenue rose 11.66% sequentially in Q1, while EBITDA rose 54.45% from ₹12.82 crore in Q4 FY26, indicating materially stronger operating profitability.
The available company commentary linked the performance to broad-based industrial demand, higher capacity utilisation, improved plant efficiency and operating mix. The September-quarter results will show whether these operating conditions continued through the first half of FY27.
For full-year FY26, the company reported operating income of ₹215.45 crore and EBITDA of ₹44.16 crore. Q1 FY27 EBITDA of ₹19.80 crore was therefore a substantial opening-quarter contribution relative to the preceding full-year operating base, although quarterly results cannot by themselves establish a full-year trend.
How does the November 6 board meeting matter to investors?
The November 6 meeting matters because it will provide the first verified update on Indo Borax’s performance after the June-quarter rise in revenue, margins and profit. Investors will be able to compare the released standalone and consolidated figures with the company’s Q1 FY27 operating momentum and the September 2025 comparative period.
The company’s Q1 FY27 board also approved the acquisition of a 64.26% stake in Kronox Lab Sciences for ₹246.12 crore. The provided disclosures do not state the completion status or financial impact of that transaction, but any formal update accompanying the results could be relevant to investors assessing capital allocation and future consolidated reporting.
The scheduled results will also cover the first half ended September 30, 2026, rather than only the July-September quarter. That provides a broader view of revenue, profitability and margins over the first six months of FY27, subject to the figures approved and disclosed by the board.
Conclusion
Indo Borax’s November 6 board meeting is a defined results event after a strong start to FY27. In Q1, revenue reached ₹70.36 crore, EBITDA rose to ₹19.80 crore and net profit increased to ₹16.25 crore, with margin expansion contributing to the improvement in earnings.
The next item to watch is the company’s formal filing of standalone and consolidated Q2 and half-year figures after the board meeting. Investors will also watch for any disclosed commentary on demand across end-use industries, operating margins and the approved Kronox Lab Sciences stake acquisition.


